Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06289140
Other study ID # BIOPTERO2
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 11, 2024
Est. completion date May 7, 2024

Study information

Verified date June 2024
Source Fundació Eurecat
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this interventional study is to to evaluate the oral bioavailability of the crystallized form of pterostilbene (ccPT) compared to its commercial free base form (pterostilbene (PT) in healthy volunteers. The main question it aims to answer are: • Do the crystallized forms of pterostilbene (ccPT) using two different encapsulation methods exhibit greater bioavailability than its commercial free base form (PT)? Participants will attend to four visits: a preselection visit (V0), a visit for the first postprandial study (V1), a visit for the second postprandial study (V2) after one-week washing period and a visit for the third postprandial study (V3) after another one week washing period. Researchers will analyze the three postprandial assays to determine which type of ccPT encapsulation provides the highest bioavailability compared to the commercial free base form (PT).


Description:

The oxidative stress (OS) is a condition where pro-oxidative processes overwhelm cellular antioxidant defenses due to disruption in redox signaling. This results in the body's inability to eliminate reactive oxygen species (ROS) or repair damages, potentially leading to severe impacts on cells, tissues, and organs. Pterostilbene (PT) is a stilbenoid found in various natural sources, emerging as an antioxidant with potential preventive and therapeutic properties in numerous diseases. Despite its promising properties, PT's low water solubility and bioavailability pose challenges. Nutraceutical co-crystallization is a recent strategy to enhance solubility and oral bioavailability. It has been identified that a new pterostilbene:picolinic acid (1:1) co-crystal, significantly increasing solubility and oral bioavailability compared to commercial free base PT. The study aims to evaluate oral bioavailability (AUC0-24h) of PT (free and total) from ccPT compared to commercial PT, using two different encapsulation methods. Secondary objectives include determining pharmacokinetic parameters such as AUCinf, relative oral bioavailability (Frel), Cmax, Tmax, and T1/2 for both free and total PT. This randomized, crossover, single-blind clinical trial aims to provide insights into the effectiveness of the new ccPT formulation in enhancing PT's oral bioavailability compared to the commercial PT formulation.


Recruitment information / eligibility

Status Completed
Enrollment 6
Est. completion date May 7, 2024
Est. primary completion date May 7, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Men and women between 18 and 65 years of age. - Sign the informed consent form. - Know how to read, write and speak Spanish Exclusion Criteria: - Take supplements or multivitamin supplements or phytotherapeutic products (especially infusions) that interfere with the treatment under study up to 30 days before the start of the study. - Be lacto-vegetarian, lacto-ovo-vegetarian, or vegan. - Present intolerances and/or food allergies related to pterostilbene or the excipients. - Be a smoker. - Having received antibiotic treatment up to 30 days before the start of the study. - Present values of body mass index = 18kg/m^2 or = 35 kg/m^2. - Present some chronic disease with clinical manifestations: coronary heart disease, cardiovascular disease, diabetes, celiac disease, Crohn's disease, chronic kidney disease, cancer, autoimmune diseases (such as fibromyalgia), respiratory and/or gastrointestinal diseases that may compromise the absorption of the compound. - Clinical history of anemia. - Being pregnant or intending to became pregnant. - Be in breastfeeding period. - Being unable to follow the study guidelines. - Participate in or have participated in a clinical trial or nutritional intervention study in the last 30 days before inclusion in the study.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Pterostilbene cocrystal (ccPT) - Gelatin capsule
Participants will intake one gelatin capsule with 75 mg of Pterostilbene cocrystal (ccPT).
Pterostilbene free form (PT)
Participants will intake one capsule with 50 mg of Pterostilbene free form (PT)
Pterostilbene cocrystal (ccPT) - Gastro-resistant capsule
Participants will intake one gastro-resistant capsule with 75 mg of Pterostilbene cocrystal (ccPT).

Locations

Country Name City State
Spain Fundació Eurecat Reus

Sponsors (2)

Lead Sponsor Collaborator
Fundació Eurecat Circe, S.L.

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Bioavailability of Pterostilbene calculated by area under the curve (AUC 0-24) of plasma pterostilbene levels, both free and total. Fasting pterostilbene levels in plasma will be determined by liquid chromatography coupled to mass spectrophotometry before consume the capsule with pterostilbene until 24 hours postprandially at 8 points after consuming the capsule (0.5 hours, 1 hours, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours and 24 hours).
Total PT will be quantified indirectly after hydrolysis of the conjugated glucuronide and sulfate metabolites to free PT in the presence of ß-glucuronidase and arylsulfatase in the plasma samples.
At week 1, week 2 and week 3
Secondary Area under the curve (AUC 0-inf) of plasma pterostilbene levels, both free and total. Fasting pterostilbene levels in plasma will be determined by liquid chromatography coupled to mass spectrophotometry before consume the capsule with pterostilbene until 24 hours postprandially at 8 points after consuming the capsule (0.5 hours, 1 hours, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours and 24 hours).
Total PT will be quantified indirectly after hydrolysis of the conjugated glucuronide and sulfate metabolites to free PT in the presence of ß-glucuronidase and arylsulfatase in the plasma samples.
At week 1, week 2 and week 3
Secondary Relative bioavailability of plasma pterostilbene levels (Frel). Relative bioavailability of plasma pterostilbene levels, both free and total At week 1, week 2 and week 3
Secondary Maximum plasma concentration (Cmax) Maximum plasma concentration of pterostilbene, total and free. At week 1, week 2 and week 3
Secondary Time for maximum plasma concentration (Tmax) Time period for the maximum plasma concentration of pterostilbene, both total and free. At week 1, week 2 and week 3
Secondary Half-life (T1/2). Time taken for half the initial dose of pterostilbene, both total and free, administered to be eliminated from the body. At week 1, week 2 and week 3
See also
  Status Clinical Trial Phase
Completed NCT05544786 - Relative Bioavailability Study of Nirmatrelvir/Ritonavir Oral Powder Relative to the Commercial Tablets and Estimation of the Effect of Food on Bioavailability of the Nirmatrelvir/Ritonavir Oral Powder in Healthy Participants. Phase 1
Completed NCT04744233 - Bioavailability of Carotenoids From Orange Juice in a Cross-over Study in Healthy Subjects. N/A
Completed NCT05561075 - Oral Bioavailability of Pterostilbene Cocrystal Compared to Its Free Form (BIOPTERO) N/A
Completed NCT03873909 - Bioavailability of Carotenoids Present in Mamey Sapote (Pouteria Sapota (Jacq.) H. E. Moore & Stearn) Fruit N/A
Completed NCT03353857 - Drug-drug Interaction Between Rifampicin and Progestins/Ethinylestradiol and Midazolam Phase 1
Completed NCT05121506 - A Study to Investigate the Bioavailability and Skin Absorption of CBD and THC From GT4 Technology in Healthy Adults Phase 1
Completed NCT01267201 - A Study Comparing Drug Availability Of Methylprednisolone In Liquid Form Versus Methylprednisolone In Tablet Form Phase 1
Completed NCT02538393 - Relative Bioavailability of Sorafenib Tablet for Oral Suspension Phase 1
Completed NCT05116982 - Effect of Three Silicon Based Food Supplements on the Urinary Excretion of Aluminum and Other Metals (SILIAL) N/A
Completed NCT04207372 - Protein Digestibility of Whey and Zein. N/A
Completed NCT01853800 - Relative Bioavailability of Oral Suspension of Rivaroxaban Compared to Standard Tablet Phase 1
Completed NCT00714584 - Pharmacokinetics of Naltrexone Following Intravenous and Oral Routes of Administration in Healthy Volunteers Phase 1
Completed NCT04876261 - Bioavailability of Hydroxytyrosol From Olive Watery Extract Supplements N/A
Completed NCT03886597 - Nutritional Intervention With Table Olives in Healthy Volunteers Phase 1/Phase 2
Completed NCT05439408 - Comparative Bioavailability of XS004 (Dasatinib) Formulation G and SPRYCEL® (Dasatinib) in Healthy, Adult Subjects Under Fasting Conditions Phase 1
Completed NCT03951025 - Study of the Bioavailability of a Food Supplement Rich in Melatonin Administered Sublingually and Orally (MELATONIN) Phase 2
Completed NCT03984916 - Study of the Bioavailability of Three Hesperidin Extracts. N/A
Completed NCT02966704 - Stable Isotope Method to Assess Dietary Protein Quality N/A
Completed NCT02847117 - Bioavailability of the Microconstituents of Natural Chios Mastiha in Healthy Adults. N/A
Completed NCT03048110 - Drug-drug Interaction (DDI) Study to Assess ODM-201 as a Victim of CYP3A4 Inhibition or Induction Phase 1